Hospital
ST Francis Hospital, INC.
ST Francis Hospital, INC. was paid $13.03M by Medicaid between Jan 2018 and Dec 2024, across 191 billing codes. Its largest line is 99283, emergency room visit (moderate) — 14% of everything it billed.
33Billing provider infoST FRANCIS HOSPITAL, INC.
GREENVILLE, SC 29615
GREENVILLE, SC 29615
33aNPI1467496802assigned 06/16/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$13.03M
24GClaims395,641
24DCodes billed191
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in South Carolina
Rank by total paid#26 of 115
Median peer was paid$2.47M
This provider vs. median5.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 50,589 | $1.60M | |
| 2019 | 52,186 | $1.48M | |
| 2020 | 40,342 | $1.17M | |
| 2021 | 63,804 | $1.80M | |
| 2022 | 75,142 | $2.61M | |
| 2023 | 62,961 | $2.57M | |
| 2024incomplete | 50,617 | $1.82M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 28,836 | 24,887 | $1.84M |
| 80053 | Comprehensive metabolic panel | 13% | 19,474 | 16,348 | $1.73M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.4% | 6,256 | 5,402 | $832K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.2% | 8,270 | 7,179 | $803K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 3.5% | 924 | 505 | $453K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.1% | 5,714 | 4,434 | $406K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.9% | 1,802 | 1,696 | $373K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.6% | 5,341 | 4,417 | $336K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2.2% | 3,527 | 3,135 | $291K |
| 81025 | 2.2% | 11,703 | 10,365 | $290K | |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.1% | 20,829 | 18,110 | $275K |
| 36415 | Collection of venous blood by venipuncture | 1.9% | 5,009 | 3,504 | $245K |
179 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.8% | 5,038 | $236K |
| 84702 | 1.8% | 3,167 | $236K | |
| 87210 | 1.8% | 2,810 | $234K | |
| 86900 | 1.7% | 2,305 | $226K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.5% | 1,856 | $192K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.4% | 1,177 | $183K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 5,952 | $181K |
| 81002 | 1.4% | 1,408 | $178K | |
| 81001 | 1.4% | 7,472 | $177K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.3% | 2,910 | $173K |
| 82962 | 1.2% | 4,859 | $156K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.2% | 5,757 | $150K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 6,208 | $142K |
| 81003 | 1.1% | 8,282 | $142K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 2,020 | $139K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 1,482 | $132K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,290 | $116K |
| 87081 | <1% | 1,210 | $107K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 953 | $106K |
| 77066 | Tomosynthesis, mammo | <1% | 870 | $104K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,739 | $98K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,895 | $97K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,019 | $94K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,632 | $92K |
| 84112 | <1% | 250 | $78K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,250 | $65K |
| 76642 | <1% | 2,308 | $62K | |
| 72100 | <1% | 1,335 | $60K | |
| 99285 | Emergency room visit (most serious) | <1% | 8,063 | $59K |
| 73562 | <1% | 892 | $57K | |
| 73630 | <1% | 852 | $57K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 22,077 | $50K |
| 93971 | <1% | 387 | $48K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,630 | $48K |
| 73610 | <1% | 422 | $44K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,028 | $44K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 452 | $35K |
| 73030 | <1% | 555 | $35K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,595 | $35K |
| 77065 | Tomosynthesis, mammo | <1% | 736 | $34K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 900 | $33K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,566 | $33K |
| 86850 | <1% | 927 | $33K | |
| 85018 | <1% | 1,297 | $32K | |
| 73130 | <1% | 326 | $32K | |
| 87807 | <1% | 329 | $32K | |
| 87186 | <1% | 623 | $31K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 251 | $29K |
| 96376 | <1% | 1,207 | $28K | |
| 87040 | <1% | 1,139 | $26K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 304 | $23K |
| 85027 | <1% | 3,681 | $19K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,532 | $18K |
| 72040 | <1% | 234 | $17K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 482 | $15K |
| G0378 | Hospital observation service, per hour | <1% | 3,531 | $14K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,259 | $13K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 904 | $11K |
| 59025 | Fetal non-stress test | <1% | 3,745 | $11K |
| 74018 | <1% | 155 | $11K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 503 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 783 | $9K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,172 | $9K |
| 76830 | Ultrasound, transvaginal | <1% | 359 | $8K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,461 | $8K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,178 | $8K |
| 97161 | <1% | 939 | $8K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,426 | $8K |
| 73110 | <1% | 59 | $7K | |
| 83735 | <1% | 4,182 | $7K | |
| 84484 | <1% | 5,662 | $7K | |
| 85379 | <1% | 1,112 | $6K | |
| 82565 | <1% | 92 | $6K | |
| 81015 | <1% | 644 | $6K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,692 | $5K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 111 | $4K |
| J2704 | Injection, propofol, 10 mg | <1% | 4,298 | $4K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 231 | $4K |
| 86140 | <1% | 848 | $4K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 31 | $3K |
| 87634 | <1% | 191 | $3K | |
| 85610 | <1% | 1,346 | $3K | |
| 87641 | <1% | 282 | $3K | |
| 82731 | <1% | 25 | $3K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 13 | $3K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,208 | $3K |
| 80050 | General health panel | <1% | 32 | $3K |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 548 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,868 | $2K |
| 74022 | <1% | 210 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 182 | $2K |
| 94760 | <1% | 1,031 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,034 | $2K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 73 | $2K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,414 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 198 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,215 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,031 | $2K |
| 87070 | <1% | 14 | $1K | |
| 88307 | <1% | 212 | $1K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,055 | $1K |
| 73502 | <1% | 70 | $1K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 499 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,587 | $1K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 49 | $1K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,596 | $996.28 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,865 | $825.61 |
| 97162 | <1% | 53 | $819.51 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 104 | $775.78 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 13 | $747.52 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 203 | $721.18 |
| 93975 | <1% | 138 | $651.24 | |
| 84550 | <1% | 149 | $550.70 | |
| 97597 | <1% | 23 | $506.57 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 37 | $482.40 |
| 82077 | <1% | 104 | $479.97 | |
| 87077 | <1% | 16 | $453.41 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 198 | $449.00 |
| 97165 | <1% | 196 | $447.56 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 222 | $414.64 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,333 | $393.74 |
| 83605 | <1% | 2,251 | $370.64 | |
| 83690 | <1% | 7,612 | $330.34 | |
| 76801 | <1% | 248 | $281.96 | |
| 84132 | <1% | 28 | $270.58 | |
| 83880 | <1% | 493 | $237.44 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 685 | $214.55 |
| 94761 | <1% | 367 | $154.00 | |
| 94762 | <1% | 285 | $129.18 | |
| 84145 | <1% | 561 | $104.88 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 785 | $58.54 |
| 85730 | <1% | 229 | $56.48 | |
| 80061 | Lipid panel | <1% | 123 | $37.62 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,027 | $18.61 |
| J3490 | Unclassified drugs | <1% | 2,287 | $14.80 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,367 | $5.12 |
| 86901 | <1% | 2,304 | $3.80 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 178 | $2.61 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 296 | $2.01 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 731 | $0.00 |
| 87088 | 0% | 281 | $0.00 | |
| J2372 | Injection, phenylephrine hydrochloride (biorphen), 20 micrograms | 0% | 44 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 303 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 703 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 120 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 90 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 46 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 21 | $0.00 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 16 | $0.00 |
| 85652 | 0% | 33 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 96 | $0.00 |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 0% | 19 | $0.00 |
| 88304 | 0% | 13 | $0.00 | |
| 86141 | 0% | 13 | $0.00 | |
| 84703 | 0% | 14 | $0.00 | |
| 83615 | 0% | 29 | $0.00 | |
| 87205 | 0% | 31 | $0.00 | |
| 94664 | 0% | 160 | $0.00 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 167 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 13 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 760 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 36 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 381 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 58 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 88 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 61 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 45 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 38 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 161 | $0.00 |
| 84156 | 0% | 15 | $0.00 | |
| 90715 | 0% | 14 | $0.00 | |
| 82570 | 0% | 44 | $0.00 | |
| C1776 | Joint device (implantable) | 0% | 44 | $0.00 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 56 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 17 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 44 | $0.00 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 19 | $0.00 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | 0% | 37 | $0.00 |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCCULLOCH, RAYMOND (CONTROLLER)
| Provider | Location | Paid |
|---|---|---|
| ST. Francis Hospital INC | Greenville, SC | $8.99M |
| ST Francis Hospital INC | Greenville, SC | $869K |
| ST Francis Hospital INC | Greenville, SC | $705K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.